With respect to ANRIL, significantly increased expressions of ANRIL have been found in cancer tissues including serous ovarian cancer (SOC), hepatocellular carcinoma (HCC), bladder cancer, ESCC and non-small-cell lung cancer, further, clinicopathologic significances of the ANRIL expressions have been found regarding clinical stage, histological grade, LNM, tumor size [18, 19, 29–31]. Here, CDKN2B-AS1 is linked to urinary bladder carcinoma.